CELL INTELLIGENCE · 肿瘤细胞治疗研究

从 CAR-T 到 CAAR-T：通过独特型导向细胞治疗重新定义 B 细胞恶性肿瘤的靶向策略

From CAR-T to CAAR-T: redefining targeting strategies in B-cell malignancies through idiotype-directed cellular therapy.

靶向连接子序列的通用高灵敏度 CAR-T 细胞监测

Universal high-sensitivity CAR T-cell monitoring by targeting linker sequences.

整合跨膜 CD28 结构域后学术性 CAR-T ARI0002h 对正常和低表达 BCMA 骨髓瘤细胞增强的抗肿瘤活性

Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane

将 CD28-TMD 整合到 ARI0002h CAR 中可增强肿瘤控制，即使在靶抗原下调的复发模型中也是如此，从而提供更好的长期疾病管理。该修饰增强了对 BCMA 表达正常和降低的 MM 肿瘤细胞系的效力，表现出更优的代谢耐力和体内活性。

靶向 CD19 CAR-T 细胞治疗的非 ICANS 神经毒性与运动及神经认知治疗中出现的不良事件：一例病例报告

Non-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: a case

事实与希望：CAR-T 细胞治疗与非霍奇金淋巴瘤免疫构成

Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma.

CRISPR/Cas9 TCR 编辑的 NKp30 CAR-T 细胞对表达 B7H6 的白血病与黑色素瘤表现出更强的抗肿瘤免疫

CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma.

超越 CAR-T：CAR-NK/T 细胞在血液肿瘤中的兴起

Beyond CAR-T: The Rise of CAR-NK/T Cells for Haematological Cancer.

CAR-NK/T 细胞可能被证明是治疗血液系统恶性肿瘤的一种更安全、更灵活的细胞疗法。

CAR-T 细胞治疗的免疫学后果：感染并发症与免疫重建分析

Immunological consequences of CAR T-cell therapy: an analysis of infectious complications and immune reconstitution.

分泌 BCMA 与 CD19 T 细胞衔接器的双靶向 STAb-T 细胞用于更好地控制血液肿瘤

Dual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of haematological cancers.

靶向 CD79b 的三种新型 CAR 用于非霍奇金淋巴瘤治疗的临床前开发及靶抗原丢失特征分析

Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target

基于特异性、疗效和靶抗原丢失，CARLY3 代表了一种针对非霍奇金淋巴瘤的潜在新型 CAR 治疗。